Veeva Systems (VEEV) 10-Q 3 Dec 21 2022 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Oct. 31, 2021	Nov. 30, 2021
Document And Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Oct. 31, 2021
Document Transition Report	false
Entity File Number	001-36121
Entity Registrant Name	Veeva Systems Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-8235463
Entity Address, Address Line One	4280 Hacienda Drive
Entity Address, City or Town	Pleasanton
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94588
City Area Code	925
Local Phone Number	452-6500
Title of 12(b) Security	Class A Common Stock,par value $0.00001 per share
Trading Symbol	VEEV
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001393052
Current Fiscal Year End Date	--01-31
Class A common stock
Document And Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		139,014,670
Class B common stock
Document And Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		14,749,523

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Oct. 31, 2021	Jan. 31, 2021
Current assets:
Cash and cash equivalents	$ 1,149,946	$ 730,504
Short-term investments	1,201,541	933,122
Accounts receivable, net of allowance for doubtful accounts of $396 and $193, respectively	211,046	564,387
Unbilled accounts receivable	67,970	47,206
Prepaid expenses and other current assets	29,292	35,607
Total current assets	2,659,795	2,310,826
Property and equipment, net	53,463	53,650
Deferred costs, net	34,091	42,072
Lease right-of-use assets	50,499	56,917
Goodwill	437,261	436,029
Intangible assets, net	102,559	114,595
Deferred income taxes	4,884	14,100
Other long-term assets	24,934	17,878
Total assets	3,367,486	3,046,067
Current liabilities:
Accounts payable	25,605	23,253
Accrued compensation and benefits	32,116	30,410
Accrued expenses and other current liabilities	36,131	30,982
Income tax payable	14,477	2,590
Deferred revenue	417,755	616,992
Lease liabilities	10,803	11,725
Total current liabilities	536,887	715,952
Deferred income taxes	1,941	1,835
Lease liabilities, noncurrent	45,237	51,393
Other long-term liabilities	14,060	10,567
Total liabilities	598,125	779,747
Commitments and contingencies
Stockholders’ equity:
Additional paid-in capital	1,145,147	965,670
Accumulated other comprehensive income (loss)	(5,738)	992
Retained earnings	1,629,950	1,299,656
Total stockholders’ equity	2,769,361	2,266,320
Total liabilities and stockholders’ equity	3,367,486	3,046,067
Class A common stock
Stockholders’ equity:
Common stock	2	2
Class B common stock
Stockholders’ equity:
Common stock	$ 0	$ 0

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Oct. 31, 2021	Jan. 31, 2021
Allowance for doubtful accounts	$ 396	$ 193
Class A common stock
Common stock, par value (in usd per share)	$ 0.00001	$ 0.00001
Common stock, shares authorized (in shares)	800,000,000	800,000,000
Common stock, shares issued (in shares)	138,914,395	137,062,817
Common stock, shares outstanding (in shares)	138,914,395	137,062,817
Class B common stock
Common stock, par value (in usd per share)	$ 0.00001	$ 0.00001
Common stock, shares authorized (in shares)	190,000,000	190,000,000
Common stock, shares issued (in shares)	14,758,023	14,993,991
Common stock, shares outstanding (in shares)	14,758,023	14,993,991

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
		Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2021	Oct. 31, 2020
Revenues:
Total revenues		$ 476,111	$ 377,519	$ 1,365,278	$ 1,068,308
Cost of revenues:
Total cost of revenues	[1]	129,564	102,997	367,797	295,081
Gross profit	[1]	346,547	274,522	997,481	773,227
Operating expenses:
Research and development	[1]	98,635	79,992	276,760	212,282
Sales and marketing	[1]	72,423	57,982	208,822	172,909
General and administrative	[1]	42,781	35,243	126,121	109,085
Total operating expenses	[1]	213,839	173,217	611,703	494,276
Operating income		132,708	101,305	385,778	278,951
Other income, net		824	3,455	7,054	9,750
Income before income taxes		133,532	104,760	392,832	288,701
Provision for income taxes		27,663	7,801	62,538	11,621
Net income		$ 105,869	$ 96,959	$ 330,294	$ 277,080
Net income per share:
Basic (in usd per share)		$ 0.69	$ 0.64	$ 2.16	$ 1.84
Diluted (in usd per share)		$ 0.65	$ 0.60	$ 2.03	$ 1.73
Weighted-average shares used to compute net income per share:
Basic (in shares)		153,514	150,993	153,020	150,322
Diluted (in shares)		163,034	161,711	162,663	160,517
Other comprehensive income:
Net change in unrealized gain (loss) on available-for-sale investments		$ (2,741)	$ (1,230)	$ (4,044)	$ 1,198
Net change in cumulative foreign currency translation gain (loss)		(308)	(1,438)	(2,686)	1,844
Comprehensive income		102,820	94,291	323,564	280,122
Subscription services
Revenues:
Total revenues		380,738	302,938	1,088,293	856,675
Cost of revenues:
Total cost of revenues	[1]	59,648	45,845	164,774	132,457
Professional services and other
Revenues:
Total revenues		95,373	74,581	276,985	211,633
Cost of revenues:
Total cost of revenues	[1]	$ 69,916	$ 57,152	$ 203,023	$ 162,624
[1]	(1) Includes stock-based compensation as follows: Cost of revenues: Cost of subscription services $ 1,292 $ 1,149 $ 3,514 $ 3,700 Cost of professional services and other 9,616 7,510 26,579 19,902 Research and development 22,311 17,685 61,463 45,523 Sales and marketing 15,102 10,711 41,772 30,089 General and administrative 13,724 11,918 39,591 36,032 Total stock-based compensation $ 62,045 $ 48,973 $ 172,919 $ 135,246

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2021	Oct. 31, 2020
Total stock-based compensation	$ 62,045	$ 48,973	$ 172,919	$ 135,246
Cost of subscription services
Total stock-based compensation	1,292	1,149	3,514	3,700
Cost of professional services and other
Total stock-based compensation	9,616	7,510	26,579	19,902
Research and development
Total stock-based compensation	22,311	17,685	61,463	45,523
Sales and marketing
Total stock-based compensation	15,102	10,711	41,772	30,089
General and administrative
Total stock-based compensation	$ 13,724	$ 11,918	$ 39,591	$ 36,032

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Class A & B common stock	Additional paid-in capital	Retained earnings	Accumulated other comprehensive income (loss)
Beginning balance (in shares) at Jan. 31, 2020		149,095,583
Beginning balance at Jan. 31, 2020	$ 1,665,594	$ 1	$ 745,475	$ 919,658	$ 460
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		1,407,370
Issuance of common stock upon exercise of stock options	25,209	$ 1	25,208
Issuance of common stock upon vesting of restricted stock units (in shares)		780,575
Stock-based compensation expense	135,454		135,454
Change in other comprehensive income (loss)	3,042				3,042
Net income	277,080			277,080
Ending balance (in shares) at Oct. 31, 2020		151,283,528
Ending balance at Oct. 31, 2020	2,106,379	$ 2	906,137	1,196,738	3,502
Beginning balance (in shares) at Jul. 31, 2020		150,739,850
Beginning balance at Jul. 31, 2020	1,956,727	$ 2	850,776	1,099,779	6,170
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		300,999
Issuance of common stock upon exercise of stock options	6,180		6,180
Issuance of common stock upon vesting of restricted stock units (in shares)		242,679
Stock-based compensation expense	49,181		49,181
Change in other comprehensive income (loss)	(2,668)				(2,668)
Net income	96,959			96,959
Ending balance (in shares) at Oct. 31, 2020		151,283,528
Ending balance at Oct. 31, 2020	2,106,379	$ 2	906,137	1,196,738	3,502
Beginning balance (in shares) at Jan. 31, 2021		152,056,808
Beginning balance at Jan. 31, 2021	$ 2,266,320	$ 2	965,670	1,299,656	992
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)	1,074,939	1,074,939
Issuance of common stock upon exercise of stock options	$ 43,310		43,310
Issuance of common stock upon vesting of restricted stock units (in shares)		663,283
Shares withheld related to net share settlement (in shares)		(122,612)
Shares withheld related to net share settlement	(37,624)		(37,624)
Stock-based compensation expense	173,791		173,791
Change in other comprehensive income (loss)	(6,730)				(6,730)
Net income	330,294			330,294
Ending balance (in shares) at Oct. 31, 2021		153,672,418
Ending balance at Oct. 31, 2021	2,769,361	$ 2	1,145,147	1,629,950	(5,738)
Beginning balance (in shares) at Jul. 31, 2021		153,358,259
Beginning balance at Jul. 31, 2021	2,620,097	$ 2	1,098,703	1,524,081	(2,689)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		185,148
Issuance of common stock upon exercise of stock options	5,368		5,368
Issuance of common stock upon vesting of restricted stock units (in shares)		197,998
Shares withheld related to net share settlement (in shares)		(68,987)
Shares withheld related to net share settlement	(21,239)		(21,239)
Stock-based compensation expense	62,315		62,315
Change in other comprehensive income (loss)	(3,049)				(3,049)
Net income	105,869			105,869
Ending balance (in shares) at Oct. 31, 2021		153,672,418
Ending balance at Oct. 31, 2021	$ 2,769,361	$ 2	$ 1,145,147	$ 1,629,950	$ (5,738)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2021	Oct. 31, 2020
Cash flows from operating activities
Net income	$ 105,869	$ 96,959	$ 330,294	$ 277,080
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	6,899	7,525	20,407	22,720
Reduction of operating lease right-of-use assets	2,855	3,322	8,556	9,411
Accretion of discount on short-term investments	1,574	1,203	4,859	1,688
Stock-based compensation	62,045	48,973	172,919	135,246
Amortization of deferred costs	6,597	5,350	19,426	15,425
Deferred income taxes	(2,021)	(1,894)	10,174	(3,532)
Loss (gain) on foreign currency from mark-to-market derivative	(65)	19	368	14
Bad debt (recovery) expense	58	(181)	195	(60)
Changes in operating assets and liabilities:
Accounts receivable	72,147	37,448	352,470	206,214
Unbilled accounts receivable	(16,870)	(16,585)	(20,764)	(20,418)
Deferred costs	(3,353)	(6,177)	(11,445)	(15,312)
Prepaid expenses and other current and long-term assets	4,407	8,195	3,278	(2,937)
Accounts payable	4,028	3,060	2,265	(456)
Accrued expenses and other current liabilities	(537)	1,541	8,646	4,357
Income taxes payable	12,010	4,538	11,993	(453)
Deferred revenue	(141,083)	(90,291)	(199,042)	(137,980)
Operating lease liabilities	(2,941)	(3,229)	(8,602)	(8,496)
Other long-term liabilities	1,340	(4,373)	4,412	384
Net cash provided by operating activities	112,959	95,403	710,409	482,895
Cash flows from investing activities
Purchases of short-term investments	(256,008)	(417,898)	(935,626)	(874,465)
Maturities and sales of short-term investments	248,093	158,628	657,062	528,194
Acquisitions, net of cash acquired	0	0	(2,133)	0
Long-term assets	(2,314)	(3,316)	(10,295)	(8,456)
Net cash used in investing activities	(10,229)	(262,586)	(290,992)	(354,727)
Cash flows from financing activities
Changes in lease liabilities - finance leases	0	79	(384)	(420)
Proceeds from exercise of common stock options	5,368	6,186	43,310	25,245
Taxes paid related to net share settlement of equity awards	(21,414)	0	(36,510)	0
Net cash (used in) provided by financing activities	(16,046)	6,265	6,416	24,825
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(1,469)	(599)	(4,414)	2,683
Net change in cash, cash equivalents, and restricted cash	85,215	(161,517)	421,419	155,676
Cash, cash equivalents, and restricted cash at beginning of period	1,067,916	796,990	731,712	479,797
Cash, cash equivalents, and restricted cash at end of period	1,153,131	635,473	1,153,131	635,473
Cash, cash equivalents, and restricted cash at end of period:
Cash and cash equivalents	1,149,946	634,265	1,149,946	634,265
Restricted cash included in other long-term assets	3,185	1,208	3,185	1,208
Cash, cash equivalents, and restricted cash at end of period	1,153,131	635,473	1,153,131	635,473
Supplemental disclosures of other cash flow information:
Cash paid for income taxes, net of refunds	14,167	2,198	34,668	17,153
Excess tax benefits from employee stock plans	10,404	17,329	45,464	59,067
Non-cash investing activities:
Changes in accounts payable and accrued expenses related to property and equipment purchases	$ (223)	$ 697	$ (2,024)	$ 1,471

Summary of Business and Signifi

Summary of Business and Significant Accounting Policies	9 Months Ended
	Oct. 31, 2021
Accounting Policies [Abstract]
Summary of Business and Significant Accounting Policies	Summary of Business and Significant Accounting Policies Description of Business Veeva is the leading provider of industry cloud solutions for the global life sciences industry. We were founded in 2007 on the premise that industry-specific cloud solutions could best address the operating challenges and regulatory requirements of life sciences companies. Our offerings span cloud software, data, analytics, professional services, and business consulting and are designed to meet the unique needs of our customers and their most strategic business functions—from research and development (R&D) to commercialization. Our solutions help life sciences companies develop and bring products to market faster and more efficiently, market and sell more effectively, and maintain compliance with government regulations. Our Commercial Solutions help life sciences companies achieve better, more intelligent engagement with healthcare professionals and healthcare organizations across multiple communication channels, and plan and execute more effective media and marketing campaigns. Our R&D Solutions for the clinical, quality, regulatory, and safety functions help life sciences companies streamline their end-to-end product development processes to increase operational efficiency and maintain regulatory compliance throughout the product life cycle. We also bring the benefits of our content and data management solutions to a set of customers outside of life sciences in other regulated industries, including, for example, consumer goods, chemicals, and cosmetics. Our fiscal year end is January 31. Principles of Consolidation and Basis of Presentation These unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting and include the accounts of our wholly-owned subsidiaries after elimination of intercompany accounts and transactions. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended January 31, 2021, filed on March 30, 2021. There have been no changes to our significant accounting policies described in the annual report that have had a material impact on our condensed consolidated financial statements and related notes. The unaudited condensed consolidated balance sheet as of January 31, 2021 included herein was derived from the audited financial statements as of that date. These unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly our financial position, results of operations, comprehensive income, and cash flows for the interim periods but are not necessarily indicative of the results of operations to be anticipated for the full fiscal year ending January 31, 2022 or any other period. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect the condensed consolidated financial statements and the notes thereto. These estimates are based on information available as of the date of the condensed consolidated financial statements. On a regular basis, management evaluates these estimates and assumptions. Items subject to such estimates and assumptions include, but are not limited to: • the standalone selling price for each distinct performance obligation included in customer contracts with multiple performance obligations; • the determination of the period of benefit for amortization of deferred costs; • the fair value of our stock-based awards. As future events cannot be determined with precision, actual results could differ significantly from those estimates. New Accounting Pronouncements Adopted in Fiscal 2022 Income Taxes In December 2019, the Financial Accounting Standards Board (FASB) issued ASU No. 2019-12, “ Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ” which simplifies accounting guidance for certain tax matters. We adopted this standard effective February 1, 2021. The adoption of this new standard did not have a material impact on our condensed consolidated financial statements.

Short-Term Investments

Short-Term Investments	9 Months Ended
	Oct. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Short-Term Investments	Short-Term Investments At October 31, 2021, short-term investments consisted of the following (in thousands): Amortized cost Gross unrealized gains Gross unrealized losses Estimated fair value Available-for-sale securities: Certificates of deposits $ 16,750 $ 10 $ — $ 16,760 Asset-backed securities 190,558 152 (458) 190,252 Commercial paper 47,375 8 — 47,383 Corporate notes and bonds 642,377 809 (1,609) 641,577 Foreign government bonds 26,625 23 (57) 26,591 U.S. agency obligations 27,974 14 (50) 27,938 U.S. treasury securities 251,320 117 (397) 251,040 Total available-for-sale securities $ 1,202,979 $ 1,133 $ (2,571) $ 1,201,541 At January 31, 2021, short-term investments consisted of the following (in thousands): Amortized cost Gross unrealized gains Gross unrealized losses Estimated fair value Available-for-sale securities: Certificates of deposits $ 17,350 $ 15 $ (1) $ 17,364 Asset-backed securities 125,833 745 (2) 126,576 Commercial paper 57,390 8 (2) 57,396 Corporate notes and bonds 428,710 2,360 (23) 431,047 Foreign government bonds 31,855 45 (2) 31,898 U.S. agency obligations 52,756 119 — 52,875 U.S. treasury securities 215,379 587 — 215,966 Total available-for-sale securities $ 929,273 $ 3,879 $ (30) $ 933,122 The following table summarizes the estimated fair value of our short-term investments, designated as available-for-sale and classified by the contractual maturity date of the securities as of the dates shown (in thousands): October 31, January 31, Due in one year or less $ 378,075 $ 428,155 Due in one to five years 823,466 504,967 Total $ 1,201,541 $ 933,122 We have not recorded an allowance for credit losses, as we believe any such losses would be immaterial based on the high credit quality of our investments. We intend to hold our securities to maturity and it is more likely than not we will hold these securities until recovery of the cost basis. The following table shows the fair values of available-for-sale securities which were in an unrealized loss position, aggregated by investment category, as of October 31, 2021 (in thousands): Held for less than 12 months Fair Gross Asset-backed securities 132,390 (458) Commercial paper 5,809 — Corporate notes and bonds 448,241 (1,609) Foreign government bonds 16,687 (57) U.S. agency obligations 24,924 (50) U.S. treasury securities 207,733 (397) The following table shows the fair values of available-for-sale securities which were in an unrealized loss position, aggregated by investment category, as of January 31, 2021 (in thousands): Held for less than 12 months Fair value Gross unrealized losses Certificates of deposits $ 3,749 $ (2) Asset-backed securities 3,318 (1) Commercial paper 17,626 (2) Corporate notes and bonds 29,558 (23) Foreign government bonds 2,679 (2)

Deferred Costs

Deferred Costs	9 Months Ended
	Oct. 31, 2021
Deferred Costs [Abstract]
Deferred Costs	Deferred CostsDeferred costs, which consist of deferred sales commissions, were $34 million and $42 million as of October 31, 2021 and January 31, 2021, respectively. Amortization expense for the deferred costs included in sales and marketing expenses in the condensed consolidated statements of comprehensive income was $7 million and $19 million for the three and nine months ended October 31, 2021, respectively, and $5 million and $15 million for the three and nine months ended October 31, 2020, respectively. There have been no impairment losses recorded in relation to the costs capitalized for any period presented.

Property and Equipment, Net

Property and Equipment, Net	9 Months Ended
	Oct. 31, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Property and Equipment, Net Property and equipment, net consists of the following as of the dates shown (in thousands): October 31, January 31, Land $ 3,040 $ 3,040 Building 20,984 20,984 Land improvements and building improvements 22,392 22,392 Equipment and computers 4,157 8,847 Furniture and fixtures 14,211 13,452 Leasehold improvements 16,499 13,945 Construction in progress 1,508 606 82,791 83,266 Less accumulated depreciation (29,328) (29,616) Total property and equipment, net $ 53,463 $ 53,650

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Oct. 31, 2021
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill was $437 million as of October 31, 2021 and $436 million as of January 31, 2021. The following schedule presents the details of intangible assets as of October 31, 2021 (dollar amounts in thousands): October 31, 2021 Gross carrying amount Accumulated amortization Net Remaining useful life (in years) Existing technology $ 26,180 $ (11,171) $ 15,009 4.0 Customer relationships 111,357 (35,976) 75,381 7.3 Trade name/trademarks 13,900 (5,980) 7,920 3.0 Other intangibles 21,405 (17,156) 4,249 5.1 $ 172,842 $ (70,283) $ 102,559 The following schedule presents the details of intangible assets as of January 31, 2021 (dollar amounts in thousands): January 31, 2021 Gross Accumulated Net Remaining Existing technology $ 26,180 $ (8,367) $ 17,813 4.8 Customer relationships 110,643 (27,741) 82,902 8.0 Trade name/trademarks 13,900 (4,005) 9,895 3.8 Other intangibles 20,453 (16,468) 3,985 5.1 $ 171,176 $ (56,581) $ 114,595 Amortization expense associated with intangible assets was $5 million and $14 million for the three and nine months ended October 31, 2021, respectively, and $5 million and $15 million for the three and nine months ended October 31, 2020, respectively. As of October 31, 2021, the estimated amortization expense for intangible assets was as follows (in thousands): Fiscal Year Estimated Remaining for 2022 $ 4,694 2023 18,623 2024 18,619 2025 17,717 2026 13,309 Thereafter 29,597 Total $ 102,559

Accrued Expenses

Accrued Expenses	9 Months Ended
	Oct. 31, 2021
Payables and Accruals [Abstract]
Accrued Expenses	Accrued Expenses Accrued expenses consisted of the following as of the dates shown (in thousands): October 31, January 31, Accrued commissions $ 7,253 $ 7,498 Accrued bonus 4,523 4,134 Accrued vacation (1) 5,688 4,716 Payroll tax payable 8,821 10,250 Accrued other compensation and benefits 5,831 3,812 Total accrued compensation and benefits $ 32,116 $ 30,410 Accrued fees payable to salesforce.com 6,605 $ 6,381 Taxes payable 12,397 13,598 Accrued third-party professional services subcontractors' fees 1,562 1,515 Other accrued expenses 15,567 9,488 Total accrued expenses and other current liabilities $ 36,131 $ 30,982 (1) Represents accrued vacation primarily for international employees. Vacation does not accrue for most U.S. employees.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Oct. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The carrying amounts of accounts receivable and other current assets, accounts payable, and accrued liabilities approximate their fair value due to their short-term nature. Financial assets and liabilities recorded at fair value in the condensed consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities are as follows: Level 1—Observable inputs, such as quoted prices in active markets for identical assets or liabilities. Level 2—Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Financial assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement requires management to make judgments and considers factors specific to the asset or liability. The following table presents the fair value hierarchy for financial assets measured at fair value on a recurring basis as of October 31, 2021 (in thousands): Level 1 Level 2 Total Assets Cash equivalents: Money market funds $ 477,352 $ — $ 477,352 U.S. treasury securities — 20,499 20,499 Corporate notes and bonds — 5,855 5,855 Short-term investments: Certificates of deposits — 16,760 16,760 Asset-backed securities — 190,252 190,252 Commercial paper — 47,383 47,383 Corporate notes and bonds — 641,577 641,577 Foreign government bonds — 26,591 26,591 U.S. agency obligations — 27,938 27,938 U.S. treasury securities — 251,040 251,040 Foreign currency derivative contracts — 72 72 Total financial assets $ 477,352 $ 1,227,967 $ 1,705,319 Liabilities Foreign currency derivative contracts $ — $ 34 $ 34 Total financial liabilities $ — $ 34 $ 34 The following table presents the fair value hierarchy for financial assets measured at fair value on a recurring basis as of January 31, 2021 (in thousands): Level 1 Level 2 Total Assets Cash equivalents: Money market funds $ 259,937 $ — $ 259,937 U.S. treasury securities — 15,520 15,520 Short-term investments: Certificates of deposits — 17,364 17,364 Asset-backed securities — 126,576 126,576 Commercial paper — 57,396 57,396 Corporate notes and bonds — 431,047 431,047 Foreign government bonds — 31,898 31,898 U.S. agency obligations — 52,875 52,875 U.S. treasury securities — 215,966 215,966 Foreign currency derivative contracts — 440 440 Total $ 259,937 $ 949,082 $ 1,209,019 Liabilities Foreign currency derivative contracts $ — $ 72 $ 72 Total $ — $ 72 $ 72 We determine the fair value of our security holdings based on pricing from our service providers and market prices from industry-standard independent data providers. The valuation techniques used to measure the fair value of financial instruments having Level 2 inputs were derived from non-binding consensus prices that are corroborated by observable market data or quoted market prices for similar instruments. Such market prices may be quoted prices in active markets for identical assets (Level 1 inputs) or pricing determined using inputs other than quoted prices that are observable either directly or indirectly (Level 2 inputs). Balance Sheet Hedges We enter into foreign currency forward contracts in order to hedge our foreign currency exposure. We account for derivative instruments at fair value with changes in the fair value recorded as a component of other income, net in our condensed consolidated statements of comprehensive income. Cash flows from such forward contracts are classified as operating activities. Foreign currency gains or losses for the three and nine months ended October 31, 2021 and 2020 were not material for any of the periods. The fair value of our outstanding derivative instruments is summarized below (in thousands): October 31, January 31, Notional amount of foreign currency derivative contracts $ 10,142 $ 52,516 Fair value of foreign currency derivative contracts 10,104 52,148 Details on outstanding balance sheet hedges are presented below as of the date shown below (in thousands): Derivatives not designated as hedging instruments Balance sheet location October 31, January 31, Derivative Assets Foreign currency derivative contracts Prepaid expenses and other current assets $ 72 $ 440 Derivative Liabilities Foreign currency derivative contracts Accrued expenses $ 34 $ 72

Income Taxes

Income Taxes	9 Months Ended
	Oct. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes For the three months ended October 31, 2021 and 2020, our effective tax rates were 20.7% and 7.4%, respectively. During the three months ended October 31, 2021, as compared to the prior year period, our effective tax rate increased primarily due to a reduction in excess tax benefits related to equity compensation and an increase in valuation allowance within certain jurisdictions. We recognized such excess tax benefits in our provision for income taxes of $10 million and $17 million for the three months ended October 31, 2021 and 2020, respectively. For the nine months ended October 31, 2021 and 2020, our effective tax rates were 15.9% and 4.0%, respectively. During the nine months ended October 31, 2021, as compared to the prior year period, our effective tax rate increased primarily due to a reduction in excess tax benefits related to equity compensation and an increase in valuation allowance within certain jurisdictions. We recognized such excess tax benefits in our provision for income taxes of $45 million and $59 million for the nine months ended October 31, 2021 and 2020, respectively.

Deferred Revenue, Performance O

Deferred Revenue, Performance Obligations, and Unbilled Accounts Receivable	9 Months Ended
	Oct. 31, 2021
Revenue Recognition and Deferred Revenue [Abstract]
Deferred Revenue, Performance Obligations, and Unbilled Accounts Receivable	Deferred Revenue, Performance Obligations, and Unbilled Accounts Receivable Of the beginning deferred revenue balance for the respective periods, we recognized $296 million and $535 million of subscription services revenue during the three and nine months ended October 31, 2021, respectively, and $232 million and $409 million for the three and nine months ended October 31, 2020, respectively. Professional services revenue recognized in the same periods from deferred revenue balances at the beginning of the respective periods was immaterial. Transaction Price Allocated to the Remaining Performance Obligations Transaction price allocated to the remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. We applied the practical expedient in accordance with ASU 2014-09, “ Revenue from Contracts with Customers ” (Topic 606) to exclude the amounts related to professional services contracts as these contracts generally have a remaining duration of one year or less. As of October 31, 2021, approximately $1,037 million of revenue is expected to be recognized from remaining performance obligations for subscription services contracts. We expect to recognize revenue on approximately 73% of these remaining performance obligations over the next 12 months, with the balance recognized thereafter. Unbilled Accounts Receivable Unbilled accounts receivable consists of (i) a receivable primarily for the revenue recognized for professional services performed but not yet billed, which were $30 million and $20 million as of October 31, 2021 and January 31, 2021, respectively, and (ii) a contract asset primarily for revenue recognized from non-cancelable, multi-year orders in which fees increase annually but for which we are not contractually able to invoice until a future period, which were $38 million and $27 million as of October 31, 2021 and January 31, 2021, respectively.

Leases

Leases	9 Months Ended
	Oct. 31, 2021
Leases [Abstract]
Leases	Leases We have operating leases for corporate offices. Our leases have various expiration dates through 2030, some of which include options to extend the leases for up to nine years. Additionally, we are the sublessor for certain office space. Our sublease income for the three and nine months ended October 31, 2021 and 2020 was immaterial. For each of the three months ended October 31, 2021 and 2020, our operating lease expense was $3 million. For each of the nine months ended October 31, 2021 and 2020, our operating lease expense was $10 million and $9 million, respectively. Supplemental cash flow information related to leases was as follows (in thousands): Nine months ended October 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 10,288 $ 8,149 Right-of-use assets obtained in exchange for lease obligations: Operating leases 2,135 8,937 Supplemental balance sheet information related to leases was as follows (in thousands, except lease term and discount rate): October 31, 2021 January 31, 2021 Operating Leases Lease right-of-use assets $ 50,499 $ 56,917 Lease liabilities $ 10,803 $ 11,347 Lease liabilities, noncurrent 45,237 51,393 Total operating lease liabilities $ 56,040 $ 62,740 Weighted Average Remaining Lease Term 6.3 years 6.7 years Weighted Average Discount Rate 3.8 % 3.8 % As of October 31, 2021, remaining maturities of operating lease liabilities are as follows (in thousands): Fiscal Year Remaining for 2022 $ 3,354 2023 11,555 2024 11,404 2025 8,490 2026 7,326 Thereafter 21,128 Total lease payments 63,257 Less imputed interest 7,217 Total $ 56,040
Leases	Leases We have operating leases for corporate offices. Our leases have various expiration dates through 2030, some of which include options to extend the leases for up to nine years. Additionally, we are the sublessor for certain office space. Our sublease income for the three and nine months ended October 31, 2021 and 2020 was immaterial. For each of the three months ended October 31, 2021 and 2020, our operating lease expense was $3 million. For each of the nine months ended October 31, 2021 and 2020, our operating lease expense was $10 million and $9 million, respectively. Supplemental cash flow information related to leases was as follows (in thousands): Nine months ended October 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 10,288 $ 8,149 Right-of-use assets obtained in exchange for lease obligations: Operating leases 2,135 8,937 Supplemental balance sheet information related to leases was as follows (in thousands, except lease term and discount rate): October 31, 2021 January 31, 2021 Operating Leases Lease right-of-use assets $ 50,499 $ 56,917 Lease liabilities $ 10,803 $ 11,347 Lease liabilities, noncurrent 45,237 51,393 Total operating lease liabilities $ 56,040 $ 62,740 Weighted Average Remaining Lease Term 6.3 years 6.7 years Weighted Average Discount Rate 3.8 % 3.8 % As of October 31, 2021, remaining maturities of operating lease liabilities are as follows (in thousands): Fiscal Year Remaining for 2022 $ 3,354 2023 11,555 2024 11,404 2025 8,490 2026 7,326 Thereafter 21,128 Total lease payments 63,257 Less imputed interest 7,217 Total $ 56,040

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Oct. 31, 2021
Share-based Payment Arrangement [Abstract]
Stockholders' Equity	Stockholders’ Equity Stock Option Activity A summary of stock option activity for the nine months ended October 31, 2021 is as follows: Number of shares Weighted average exercise price Weighted average remaining contractual term (in years) Aggregate Options outstanding at January 31, 2021 12,761,289 $ 57.48 5.0 $ 2,794 Options granted 1,081,518 278.07 Options exercised (1,074,939) 40.29 Options forfeited/cancelled (267,795) 166.28 Options outstanding at October 31, 2021 12,500,073 $ 75.71 4.8 $ 3,016 Options vested and exercisable at October 31, 2021 7,197,020 $ 28.82 2.8 $ 2,074 Options vested and exercisable at October 31, 2021 and expected to vest thereafter 12,500,073 $ 75.71 4.8 $ 3,016 The options granted during the nine months ended October 31, 2021 were predominantly made in connection with our annual performance review cycle. The weighted average grant-date fair value of options granted was $117.20 and $108.90 per option for the three and nine months ended October 31, 2021, respectively. As of October 31, 2021, there was $250 million in unrecognized compensation cost related to unvested stock options granted under the 2012 Equity Incentive Plan and 2013 Equity Incentive Plan. This cost is expected to be recognized over a weighted average period of 2.8 years. As of October 31, 2021, we had authorized and unissued shares of common stock sufficient to satisfy exercises of stock options. The total intrinsic value of options exercised was approximately $52 million and $267 million for the three and nine months ended October 31, 2021, respectively. Stock-Based Compensation The following table presents the weighted-average assumptions used to estimate the grant date fair value of options granted during the periods presented: Three months ended October 31, Nine months ended October 31, 2021 2020 2021 2020 Volatility 37% 39% - 40% 37% - 39% 39% - 41% Expected term (in years) 6.25 6.25 6.25 6.25 - 7.25 Risk-free interest rate 0.90 % - 1.30 % 0.33 % - 0.45 % 0.68 % - 1.30 % 0.33 % - 1.43 % Dividend yield —% —% —% —% Restricted Stock Units A summary of restricted stock unit (RSU) activity for the nine months ended October 31, 2021 is as follows: Unreleased restricted stock units Weighted average grant date fair value Balance at January 31, 2021 1,032,215 $ 121.98 RSUs granted 442,514 280.61 RSUs vested (663,283) 164.02 RSUs forfeited/cancelled (57,443) 177.20 Balance at October 31, 2021 754,003 173.86

Net Income per Share

Net Income per Share	9 Months Ended
	Oct. 31, 2021
Earnings Per Share [Abstract]
Net Income per Share	Net Income per Share Basic net income per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing net income by the weighted-average shares outstanding, including potentially dilutive shares of common equivalents outstanding during the period. The dilutive effect of potential shares of common stock are determined using the treasury stock method. The computation of fully diluted net income per share of Class A common stock assumes the conversion from Class B common stock, while the fully diluted net income per share of Class B common stock does not assume the conversion of those shares. The numerators and denominators of the basic and diluted net income per share computations for our common stock are calculated as follows (in thousands, except per share data): Three months ended October 31, Nine months ended October 31, 2021 2020 2021 2020 Class A Class B Class A Class B Class A Class B Class A Class B Basic Numerator Net income, basic $ 95,691 $ 10,178 $ 87,262 $ 9,697 $ 298,379 $ 31,915 $ 249,155 $ 27,925 Denominator Weighted average shares used in computing net income per share, basic 138,755 14,759 135,892 15,101 138,234 14,786 135,172 15,150 Net income per share, basic $ 0.69 $ 0.69 $ 0.64 $ 0.64 $ 2.16 $ 2.16 $ 1.84 $ 1.84 Diluted Numerator Net income, basic $ 95,691 $ 10,178 $ 87,262 $ 9,697 $ 298,379 $ 31,915 $ 249,155 $ 27,925 Reallocation as a result of conversion of Class B to Class A common stock: Net income, basic 10,178 — 9,697 — 31,915 — 27,925 — Reallocation of net income to Class B common stock — 5,588 — 5,784 — 17,690 — 15,825 Net income, diluted $ 105,869 $ 15,766 $ 96,959 $ 15,481 $ 330,294 $ 49,605 $ 277,080 $ 43,750 Denominator Number of shares used for basic net income per share computation 138,755 14,759 135,892 15,101 138,234 14,786 135,172 15,150 Conversion of Class B to Class A common stock 14,759 — 15,101 — 14,786 — 15,150 — Effect of potentially dilutive common shares 9,520 9,520 10,718 10,718 9,643 9,643 10,195 10,195 Weighted average shares used in computing net income per share, diluted 163,034 24,279 161,711 25,819 162,663 24,429 160,517 25,345 Net income per share, diluted $ 0.65 $ 0.65 $ 0.60 $ 0.60 $ 2.03 $ 2.03 $ 1.73 $ 1.73 Potential common share equivalents excluded where the inclusion would be anti-dilutive are as follows: Three months ended October 31, Nine months ended October 31, 2021 2020 2021 2020 Options and awards to purchase shares not included in the computation of diluted net income per share because their inclusion would be anti-dilutive 1,105,478 85,099 869,044 997,236

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Oct. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Litigation IQVIA Litigation Matters Veeva OpenData and Veeva Network Action. On January 10, 2017, IQVIA Inc. (formerly Quintiles IMS Incorporated) and IMS Software Services, Ltd. (collectively, “IQVIA”) filed a complaint against us in the U.S. District Court for the District of New Jersey (IQVIA Inc. v. Veeva Systems Inc. (No. 2:17-cv-00177)) (OpenData and Network Action). In the complaint, IQVIA alleges that we used unauthorized access to proprietary IQVIA data to improve our software and data products and that our software is designed to steal IQVIA trade secrets. IQVIA further alleges that we have intentionally gained unauthorized access to IQVIA proprietary information to gain an unfair advantage in marketing our products and that we have made false statements concerning IQVIA’s conduct and our data security capabilities. IQVIA asserts claims under both federal and state misappropriation of trade secret laws, federal false advertising law, and common law claims for unjust enrichment, tortious interference, and unfair trade practices. The complaint seeks declaratory and injunctive relief and unspecified monetary damages. On March 13, 2017, we filed our answer denying IQVIA's claims and filed counterclaims. Our counterclaims allege that IQVIA, as the dominant provider of data for life sciences companies, has abused monopoly power to exclude Veeva OpenData and Veeva Network from their respective markets. The counterclaims allege that IQVIA has engaged in various tactics to prevent customers from using our applications and has deliberately raised costs and increased the difficulty of attempting to switch from IQVIA data to our data products. As amended, our counterclaims assert federal and state antitrust claims, as well as claims under California’s Unfair Practices Act and common law claims for intentional interference with contractual relations, intentional interference with prospective economic advantage, and negligent misrepresentation. The counterclaims seek injunctive relief, monetary damages exceeding $200 million, and attorneys’ fees. On October 3, 2018, the court denied IQVIA’s motion to dismiss our antitrust claims. On February 18, 2020, IQVIA filed a motion for sanctions against Veeva, seeking default judgment and dismissal and, in the alternative, an adverse inference at trial related to discovery disputes. On May 7, 2021, the special master appointed to oversee litigation discovery ruled against IQVIA’s request for default judgment and dismissal and ruled in IQVIA’s favor with respect to certain other matters, including recommending to the trial judge that a permissive adverse inference instruction be issued to the jury with respect to certain documents that were not preserved by Veeva. Should the trial judge accept the recommendation, the jury would be permitted, but not required, to infer that certain evidence not preserved by Veeva would have been unfavorable to Veeva, if the jury first concludes that Veeva controlled the evidence, that the evidence was relevant, and that Veeva should have preserved the evidence. The jury is also likely to be instructed that it may also consider whether the non-preserved evidence was duplicative of other evidence produced by Veeva and whether Veeva’s conduct was reasonable in light of all circumstances. Veeva was also ordered to pay IQVIA’s fees and expenses incurred in connection with portions of its sanctions motion. On June 4, 2021, we appealed the special master’s ruling and IQVIA’s fee award to the federal district court judge. Fact discovery is largely complete and expert discovery is scheduled to conclude on September 8, 2022. While it is not possible at this time to predict with any degree of certainty the ultimate outcome of this action, and we are unable to make a meaningful estimate of the amount or range of gain or loss, if any, that could result from the OpenData and Network Action, we believe that IQVIA’s claims lack merit and that our counterclaims warrant injunctive relief and monetary damages for Veeva. Veeva Nitro Action. On July 17, 2019, IQVIA filed a lawsuit in the U.S. District Court for the District of New Jersey (IQVIA Inc. v. Veeva Systems Inc. (No. 2:19-cv-15517)) (IQVIA Declaratory Action) seeking a declaratory judgment that IQVIA is not liable to Veeva for disallowing use of IQVIA’s data products in Veeva Nitro or any later-introduced Veeva software products. The IQVIA Declaratory Action does not seek any monetary relief. On July 18, 2019, we filed a lawsuit against IQVIA in the U.S. District Court for the Northern District of California (Veeva Systems Inc. v. IQVIA Inc. (No. 3:19-cv-04137)) (Veeva Nitro Action), alleging that IQVIA engaged in anticompetitive conduct as to Veeva Nitro. Our complaint asserts federal and state antitrust claims, as well as claims under California’s Unfair Competition Law and common law claims for intentional interference with contractual relations and intentional interference with prospective economic advantage. The complaint seeks injunctive relief and monetary damages. IQVIA filed its answer and affirmative defenses on September 5, 2019. On September 26, 2019, the Northern District of California transferred the Veeva Nitro Action to the District of New Jersey (Veeva Systems Inc. v. IQVIA Inc. (No. 2:19-cv-18558)). On March 24, 2020, we amended our complaint in the Veeva Nitro Action to include allegations of IQVIA’s anticompetitive conduct as to additional Veeva software applications, such as Veeva Andi, Veeva Align, and Veeva Vault MedComms; additional examples of IQVIA’s monopolistic behavior against Veeva Nitro; IQVIA’s unlawful access of Veeva’s proprietary software products; and a request for declaratory relief. IQVIA answered the amended complaint on May 22, 2020. On August 21, 2020, the District of New Jersey consolidated the Veeva Nitro Action and IQVIA Declaratory Action, and stayed both actions pending conclusion of the OpenData and Network Action. On September 21, 2021, the court lifted the stay and, on November 8, 2021, entered a pretrial scheduling order that set the close of fact discovery for April 22, 2022, and the close of expert discovery for September 8, 2022. While it is not possible at this time to predict with any degree of certainty the ultimate outcome of this action, we believe that our claims warrant injunctive and declaratory relief and monetary damages for Veeva and against IQVIA. Fee Arrangements Related to the IQVIA Litigation Matters. We have entered into partial contingency fee arrangements with certain law firms representing us in the IQVIA litigations. Pursuant to those arrangements, such law firms are entitled to an agreed portion of any damages we recover from IQVIA (Contingency Fees) or may be entitled to payment of additional fees from us based on the achievement of certain outcomes (Success Fees). While it is reasonably possible that we may incur such Success Fees, we are unable to make an estimate of any such liability and have not accrued any liability related to Success Fees at this time. Medidata Litigation Matter On January 26, 2017, Medidata Solutions, Inc. filed a complaint in the U.S. District Court for the Southern District of New York ( Medidata Solutions, Inc. v. Veeva Systems Inc. et al. (No. 1:17-cv-00589)) against us and five individual Veeva employees who previously worked for Medidata (“Individual Employees”). The complaint alleged that we induced and conspired with the Individual Employees to breach their employment agreements, including non-compete and confidentiality provisions, and to misappropriate Medidata’s confidential and trade secret information. The complaint sought declaratory and injunctive relief, unspecified monetary damages, and attorneys’ fees. Medidata has since amended its complaint twice, asserting the same claims with additional factual allegations, and has voluntarily dismissed the Individual Defendants without prejudice. Fact discovery is now completed. On April 24, 2020, Medidata filed a motion for partial summary judgment on its claims for trade secret misappropriation as well as several of Veeva’s affirmative defenses. On May 15, 2020, we filed a motion for summary judgment on all of Medidata’s claims. On February 9, 2021, the court issued its ruling granting summary judgment in favor of Veeva as to certain of Medidata's claims and in favor of Medidata as to certain of Veeva's affirmative defenses. A trial date has not been set. While it is not possible at this time to predict with any degree of certainty the ultimate outcome of this action, and we are unable to make a meaningful estimate of the amount or range of loss, if any, that could result from any unfavorable outcome, we believe that Medidata’s claims lack merit. Other Litigation Matters From time to time, we may be involved in other legal proceedings and subject to claims incident to the ordinary course of business. Although the results of such legal proceedings and claims cannot be predicted with certainty, we believe we are not currently a party to any other legal proceedings, the outcome of which, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, cash flows or financial position. Regardless of the outcome, such proceedings can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.

Revenues by Product

Revenues by Product	9 Months Ended
	Oct. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenues by Product	Revenues by Product Prior to the fiscal quarter ended October 31, 2021, we grouped our revenues into two product areas: Commercial Cloud and Vault. During the fiscal quarter ended October 31, 2021, we changed the product areas under which we group revenues to Commercial Solutions and R&D Solutions to better align with how we manage our business and to reflect the principal functions served by our products. Commercial Solutions consist of our cloud software, data, and analytics products built specifically to more efficiently and effectively commercialize our customers’ products. R&D Solutions consist of our clinical, quality, regulatory, and safety products. Specifically, revenues attributable to Vault PromoMats and Vault MedComms, applications used for commercial operations, are now reflected in Commercial Solutions. The prior period revenue balances in the table below have been adjusted to reflect the current period presentation of our product areas. There were no changes to the aggregate amounts reported within our condensed consolidated statements of comprehensive income. Total revenues consist of the following (in thousands): Three months ended October 31, Nine months ended October 31, 2021 2020 2021 2020 Subscription services Commercial Solutions $ 223,183 $ 189,874 $ 649,156 $ 547,341 R&D Solutions 157,555 113,064 439,137 309,334 Total subscription services $ 380,738 $ 302,938 $ 1,088,293 $ 856,675 Professional services Commercial Solutions $ 41,675 $ 36,613 $ 124,241 $ 104,859 R&D Solutions 53,698 37,968 152,744 106,774 Total professional services $ 95,373 $ 74,581 $ 276,985 $ 211,633 Total revenues $ 476,111 $ 377,519 $ 1,365,278 $ 1,068,308

Information about Geographic Ar

Information about Geographic Areas	9 Months Ended
	Oct. 31, 2021
Segment Reporting [Abstract]
Information about Geographic Areas	Information about Geographic AreasWe track and allocate revenues by principal geographic area rather than by individual country, which makes it impractical to disclose revenues for the United States or other specific foreign countries. We measure subscription services revenue primarily by the estimated location of the end users in each geographic area for our Commercial Solutions and primarily by the estimated location of usage in each geographic area for our R&D Solutions. We measure professional services revenue primarily by the location of the resources performing the professional services. Total revenues by geographic area were as follows for the periods shown below (in thousands): Three months ended October 31, Nine months ended October 31, 2021 2020 2021 2020 Revenues by geography North America $ 277,165 $ 218,110 $ 782,590 $ 614,101 Europe 128,032 102,440 376,885 290,257 Asia Pacific 57,837 46,178 167,319 133,039 Middle East, Africa, and Latin America 13,077 10,791 38,484 30,911 Total revenues $ 476,111 $ 377,519 $ 1,365,278 $ 1,068,308 Long-lived assets by geographic area are as follows as of the periods shown below (in thousands): October 31, January 31, Long-lived assets by geography North America $ 45,702 $ 46,285 Europe 5,285 5,525 Asia Pacific 1,368 1,359 Middle East, Africa, and Latin America $ 1,108 481 Total long-lived assets $ 53,463 $ 53,650

Summary of Business and Signi_2

Summary of Business and Significant Accounting Policies (Policies)	9 Months Ended
	Oct. 31, 2021
Accounting Policies [Abstract]
Description of Business	Description of Business Veeva is the leading provider of industry cloud solutions for the global life sciences industry. We were founded in 2007 on the premise that industry-specific cloud solutions could best address the operating challenges and regulatory requirements of life sciences companies. Our offerings span cloud software, data, analytics, professional services, and business consulting and are designed to meet the unique needs of our customers and their most strategic business functions—from research and development (R&D) to commercialization. Our solutions help life sciences companies develop and bring products to market faster and more efficiently, market and sell more effectively, and maintain compliance with government regulations. Our Commercial Solutions help life sciences companies achieve better, more intelligent engagement with healthcare professionals and healthcare organizations across multiple communication channels, and plan and execute more effective media and marketing campaigns. Our R&D Solutions for the clinical, quality, regulatory, and safety functions help life sciences companies streamline their end-to-end product development processes to increase operational efficiency and maintain regulatory compliance throughout the product life cycle. We also bring the benefits of our content and data management solutions to a set of customers outside of life sciences in other regulated industries, including, for example, consumer goods, chemicals, and cosmetics. Our fiscal year end is January 31.
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation These unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting and include the accounts of our wholly-owned subsidiaries after elimination of intercompany accounts and transactions. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended January 31, 2021, filed on March 30, 2021. There have been no changes to our significant accounting policies described in the annual report that have had a material impact on our condensed consolidated financial statements and related notes. The unaudited condensed consolidated balance sheet as of January 31, 2021 included herein was derived from the audited financial statements as of that date. These unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly our financial position, results of operations, comprehensive income, and cash flows for the interim periods but are not necessarily indicative of the results of operations to be anticipated for the full fiscal year ending January 31, 2022 or any other period.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect the condensed consolidated financial statements and the notes thereto. These estimates are based on information available as of the date of the condensed consolidated financial statements. On a regular basis, management evaluates these estimates and assumptions. Items subject to such estimates and assumptions include, but are not limited to: • the standalone selling price for each distinct performance obligation included in customer contracts with multiple performance obligations; • the determination of the period of benefit for amortization of deferred costs; • the fair value of our stock-based awards. As future events cannot be determined with precision, actual results could differ significantly from those estimates.
New Accounting Pronouncements Adopted in Fiscal 2022	New Accounting Pronouncements Adopted in Fiscal 2022 Income Taxes In December 2019, the Financial Accounting Standards Board (FASB) issued ASU No. 2019-12, “ Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ” which simplifies accounting guidance for certain tax matters. We adopted this standard effective February 1, 2021. The adoption of this new standard did not have a material impact on our condensed consolidated financial statements.
Fair Value Measurements	Financial assets and liabilities recorded at fair value in the condensed consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities are as follows: Level 1—Observable inputs, such as quoted prices in active markets for identical assets or liabilities. Level 2—Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Financial assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement requires management to make judgments and considers factors specific to the asset or liability.
Net Income per Share Attributable to Common Stockholders	Basic net income per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing net income by the weighted-average shares outstanding, including potentially dilutive shares of common equivalents outstanding during the period. The dilutive effect of potential shares of common stock are determined using the treasury stock method. The computation of fully diluted net income per share of Class A common stock assumes the conversion from Class B common stock, while the fully diluted net income per share of Class B common stock does not assume the conversion of those shares.

Short-Term Investments (Tables)

Short-Term Investments (Tables)	9 Months Ended
	Oct. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Schedule of Short-Term Investments	At October 31, 2021, short-term investments consisted of the following (in thousands): Amortized cost Gross unrealized gains Gross unrealized losses Estimated fair value Available-for-sale securities: Certificates of deposits $ 16,750 $ 10 $ — $ 16,760 Asset-backed securities 190,558 152 (458) 190,252 Commercial paper 47,375 8 — 47,383 Corporate notes and bonds 642,377 809 (1,609) 641,577 Foreign government bonds 26,625 23 (57) 26,591 U.S. agency obligations 27,974 14 (50) 27,938 U.S. treasury securities 251,320 117 (397) 251,040 Total available-for-sale securities $ 1,202,979 $ 1,133 $ (2,571) $ 1,201,541 At January 31, 2021, short-term investments consisted of the following (in thousands): Amortized cost Gross unrealized gains Gross unrealized losses Estimated fair value Available-for-sale securities: Certificates of deposits $ 17,350 $ 15 $ (1) $ 17,364 Asset-backed securities 125,833 745 (2) 126,576 Commercial paper 57,390 8 (2) 57,396 Corporate notes and bonds 428,710 2,360 (23) 431,047 Foreign government bonds 31,855 45 (2) 31,898 U.S. agency obligations 52,756 119 — 52,875 U.S. treasury securities 215,379 587 — 215,966 Total available-for-sale securities $ 929,273 $ 3,879 $ (30) $ 933,122 The following table summarizes the estimated fair value of our short-term investments, designated as available-for-sale and classified by the contractual maturity date of the securities as of the dates shown (in thousands): October 31, January 31, Due in one year or less $ 378,075 $ 428,155 Due in one to five years 823,466 504,967 Total $ 1,201,541 $ 933,122
Schedule of Fair Values and Gross Unrealized Loss Position of Available-for-Sale Securities Aggregated by Investment Category	The following table shows the fair values of available-for-sale securities which were in an unrealized loss position, aggregated by investment category, as of October 31, 2021 (in thousands): Held for less than 12 months Fair Gross Asset-backed securities 132,390 (458) Commercial paper 5,809 — Corporate notes and bonds 448,241 (1,609) Foreign government bonds 16,687 (57) U.S. agency obligations 24,924 (50) U.S. treasury securities 207,733 (397) The following table shows the fair values of available-for-sale securities which were in an unrealized loss position, aggregated by investment category, as of January 31, 2021 (in thousands): Held for less than 12 months Fair value Gross unrealized losses Certificates of deposits $ 3,749 $ (2) Asset-backed securities 3,318 (1) Commercial paper 17,626 (2) Corporate notes and bonds 29,558 (23) Foreign government bonds 2,679 (2)

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	9 Months Ended
	Oct. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net consists of the following as of the dates shown (in thousands): October 31, January 31, Land $ 3,040 $ 3,040 Building 20,984 20,984 Land improvements and building improvements 22,392 22,392 Equipment and computers 4,157 8,847 Furniture and fixtures 14,211 13,452 Leasehold improvements 16,499 13,945 Construction in progress 1,508 606 82,791 83,266 Less accumulated depreciation (29,328) (29,616) Total property and equipment, net $ 53,463 $ 53,650

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Oct. 31, 2021
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Details of Intangible Assets	The following schedule presents the details of intangible assets as of October 31, 2021 (dollar amounts in thousands): October 31, 2021 Gross carrying amount Accumulated amortization Net Remaining useful life (in years) Existing technology $ 26,180 $ (11,171) $ 15,009 4.0 Customer relationships 111,357 (35,976) 75,381 7.3 Trade name/trademarks 13,900 (5,980) 7,920 3.0 Other intangibles 21,405 (17,156) 4,249 5.1 $ 172,842 $ (70,283) $ 102,559 The following schedule presents the details of intangible assets as of January 31, 2021 (dollar amounts in thousands): January 31, 2021 Gross Accumulated Net Remaining Existing technology $ 26,180 $ (8,367) $ 17,813 4.8 Customer relationships 110,643 (27,741) 82,902 8.0 Trade name/trademarks 13,900 (4,005) 9,895 3.8 Other intangibles 20,453 (16,468) 3,985 5.1 $ 171,176 $ (56,581) $ 114,595
Estimated Amortization Expense	As of October 31, 2021, the estimated amortization expense for intangible assets was as follows (in thousands): Fiscal Year Estimated Remaining for 2022 $ 4,694 2023 18,623 2024 18,619 2025 17,717 2026 13,309 Thereafter 29,597 Total $ 102,559

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Oct. 31, 2021
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following as of the dates shown (in thousands): October 31, January 31, Accrued commissions $ 7,253 $ 7,498 Accrued bonus 4,523 4,134 Accrued vacation (1) 5,688 4,716 Payroll tax payable 8,821 10,250 Accrued other compensation and benefits 5,831 3,812 Total accrued compensation and benefits $ 32,116 $ 30,410 Accrued fees payable to salesforce.com 6,605 $ 6,381 Taxes payable 12,397 13,598 Accrued third-party professional services subcontractors' fees 1,562 1,515 Other accrued expenses 15,567 9,488 Total accrued expenses and other current liabilities $ 36,131 $ 30,982 (1) Represents accrued vacation primarily for international employees. Vacation does not accrue for most U.S. employees.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Oct. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table presents the fair value hierarchy for financial assets measured at fair value on a recurring basis as of October 31, 2021 (in thousands): Level 1 Level 2 Total Assets Cash equivalents: Money market funds $ 477,352 $ — $ 477,352 U.S. treasury securities — 20,499 20,499 Corporate notes and bonds — 5,855 5,855 Short-term investments: Certificates of deposits — 16,760 16,760 Asset-backed securities — 190,252 190,252 Commercial paper — 47,383 47,383 Corporate notes and bonds — 641,577 641,577 Foreign government bonds — 26,591 26,591 U.S. agency obligations — 27,938 27,938 U.S. treasury securities — 251,040 251,040 Foreign currency derivative contracts — 72 72 Total financial assets $ 477,352 $ 1,227,967 $ 1,705,319 Liabilities Foreign currency derivative contracts $ — $ 34 $ 34 Total financial liabilities $ — $ 34 $ 34 The following table presents the fair value hierarchy for financial assets measured at fair value on a recurring basis as of January 31, 2021 (in thousands): Level 1 Level 2 Total Assets Cash equivalents: Money market funds $ 259,937 $ — $ 259,937 U.S. treasury securities — 15,520 15,520 Short-term investments: Certificates of deposits — 17,364 17,364 Asset-backed securities — 126,576 126,576 Commercial paper — 57,396 57,396 Corporate notes and bonds — 431,047 431,047 Foreign government bonds — 31,898 31,898 U.S. agency obligations — 52,875 52,875 U.S. treasury securities — 215,966 215,966 Foreign currency derivative contracts — 440 440 Total $ 259,937 $ 949,082 $ 1,209,019 Liabilities Foreign currency derivative contracts $ — $ 72 $ 72 Total $ — $ 72 $ 72
Summary Fair Value of Outstanding Derivative Instruments	The fair value of our outstanding derivative instruments is summarized below (in thousands): October 31, January 31, Notional amount of foreign currency derivative contracts $ 10,142 $ 52,516 Fair value of foreign currency derivative contracts 10,104 52,148
Summary of Outstanding Balance Sheet Hedges	Details on outstanding balance sheet hedges are presented below as of the date shown below (in thousands): Derivatives not designated as hedging instruments Balance sheet location October 31, January 31, Derivative Assets Foreign currency derivative contracts Prepaid expenses and other current assets $ 72 $ 440 Derivative Liabilities Foreign currency derivative contracts Accrued expenses $ 34 $ 72

Leases (Tables)

Leases (Tables)	9 Months Ended
	Oct. 31, 2021
Leases [Abstract]
Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases was as follows (in thousands): Nine months ended October 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 10,288 $ 8,149 Right-of-use assets obtained in exchange for lease obligations: Operating leases 2,135 8,937
Supplemental Balance Sheet Information Related to Leases	Supplemental balance sheet information related to leases was as follows (in thousands, except lease term and discount rate): October 31, 2021 January 31, 2021 Operating Leases Lease right-of-use assets $ 50,499 $ 56,917 Lease liabilities $ 10,803 $ 11,347 Lease liabilities, noncurrent 45,237 51,393 Total operating lease liabilities $ 56,040 $ 62,740 Weighted Average Remaining Lease Term 6.3 years 6.7 years Weighted Average Discount Rate 3.8 % 3.8 %
Maturity of Operating Lease Liabilities	As of October 31, 2021, remaining maturities of operating lease liabilities are as follows (in thousands): Fiscal Year Remaining for 2022 $ 3,354 2023 11,555 2024 11,404 2025 8,490 2026 7,326 Thereafter 21,128 Total lease payments 63,257 Less imputed interest 7,217 Total $ 56,040

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Oct. 31, 2021
Share-based Payment Arrangement [Abstract]
Summary of Stock Option Activity	A summary of stock option activity for the nine months ended October 31, 2021 is as follows: Number of shares Weighted average exercise price Weighted average remaining contractual term (in years) Aggregate Options outstanding at January 31, 2021 12,761,289 $ 57.48 5.0 $ 2,794 Options granted 1,081,518 278.07 Options exercised (1,074,939) 40.29 Options forfeited/cancelled (267,795) 166.28 Options outstanding at October 31, 2021 12,500,073 $ 75.71 4.8 $ 3,016 Options vested and exercisable at October 31, 2021 7,197,020 $ 28.82 2.8 $ 2,074 Options vested and exercisable at October 31, 2021 and expected to vest thereafter 12,500,073 $ 75.71 4.8 $ 3,016
Schedule of Weighted-Average Assumptions Used to Estimate Grant Date Fair Value of Options Granted	The following table presents the weighted-average assumptions used to estimate the grant date fair value of options granted during the periods presented: Three months ended October 31, Nine months ended October 31, 2021 2020 2021 2020 Volatility 37% 39% - 40% 37% - 39% 39% - 41% Expected term (in years) 6.25 6.25 6.25 6.25 - 7.25 Risk-free interest rate 0.90 % - 1.30 % 0.33 % - 0.45 % 0.68 % - 1.30 % 0.33 % - 1.43 % Dividend yield —% —% —% —%
Summary of Restricted Stock Unit (RSU) Activity	A summary of restricted stock unit (RSU) activity for the nine months ended October 31, 2021 is as follows: Unreleased restricted stock units Weighted average grant date fair value Balance at January 31, 2021 1,032,215 $ 121.98 RSUs granted 442,514 280.61 RSUs vested (663,283) 164.02 RSUs forfeited/cancelled (57,443) 177.20 Balance at October 31, 2021 754,003 173.86

Net Income per Share (Tables)

Net Income per Share (Tables)	9 Months Ended
	Oct. 31, 2021
Earnings Per Share [Abstract]
Numerators and Denominators of the Basic and Diluted EPS Computations for Common Stock	The numerators and denominators of the basic and diluted net income per share computations for our common stock are calculated as follows (in thousands, except per share data): Three months ended October 31, Nine months ended October 31, 2021 2020 2021 2020 Class A Class B Class A Class B Class A Class B Class A Class B Basic Numerator Net income, basic $ 95,691 $ 10,178 $ 87,262 $ 9,697 $ 298,379 $ 31,915 $ 249,155 $ 27,925 Denominator Weighted average shares used in computing net income per share, basic 138,755 14,759 135,892 15,101 138,234 14,786 135,172 15,150 Net income per share, basic $ 0.69 $ 0.69 $ 0.64 $ 0.64 $ 2.16 $ 2.16 $ 1.84 $ 1.84 Diluted Numerator Net income, basic $ 95,691 $ 10,178 $ 87,262 $ 9,697 $ 298,379 $ 31,915 $ 249,155 $ 27,925 Reallocation as a result of conversion of Class B to Class A common stock: Net income, basic 10,178 — 9,697 — 31,915 — 27,925 — Reallocation of net income to Class B common stock — 5,588 — 5,784 — 17,690 — 15,825 Net income, diluted $ 105,869 $ 15,766 $ 96,959 $ 15,481 $ 330,294 $ 49,605 $ 277,080 $ 43,750 Denominator Number of shares used for basic net income per share computation 138,755 14,759 135,892 15,101 138,234 14,786 135,172 15,150 Conversion of Class B to Class A common stock 14,759 — 15,101 — 14,786 — 15,150 — Effect of potentially dilutive common shares 9,520 9,520 10,718 10,718 9,643 9,643 10,195 10,195 Weighted average shares used in computing net income per share, diluted 163,034 24,279 161,711 25,819 162,663 24,429 160,517 25,345 Net income per share, diluted $ 0.65 $ 0.65 $ 0.60 $ 0.60 $ 2.03 $ 2.03 $ 1.73 $ 1.73
Potential Common Share Equivalents Excluded where the Inclusion would be Anti-dilutive	Potential common share equivalents excluded where the inclusion would be anti-dilutive are as follows: Three months ended October 31, Nine months ended October 31, 2021 2020 2021 2020 Options and awards to purchase shares not included in the computation of diluted net income per share because their inclusion would be anti-dilutive 1,105,478 85,099 869,044 997,236

Revenues by Product (Tables)

Revenues by Product (Tables)	9 Months Ended
	Oct. 31, 2021
Revenue from Contract with Customer [Abstract]
Summary of Total Revenues	Total revenues consist of the following (in thousands): Three months ended October 31, Nine months ended October 31, 2021 2020 2021 2020 Subscription services Commercial Solutions $ 223,183 $ 189,874 $ 649,156 $ 547,341 R&D Solutions 157,555 113,064 439,137 309,334 Total subscription services $ 380,738 $ 302,938 $ 1,088,293 $ 856,675 Professional services Commercial Solutions $ 41,675 $ 36,613 $ 124,241 $ 104,859 R&D Solutions 53,698 37,968 152,744 106,774 Total professional services $ 95,373 $ 74,581 $ 276,985 $ 211,633 Total revenues $ 476,111 $ 377,519 $ 1,365,278 $ 1,068,308

Information about Geographic _2

Information about Geographic Areas (Tables)	9 Months Ended
	Oct. 31, 2021
Segment Reporting [Abstract]
Revenues by Geographic Area	Total revenues by geographic area were as follows for the periods shown below (in thousands): Three months ended October 31, Nine months ended October 31, 2021 2020 2021 2020 Revenues by geography North America $ 277,165 $ 218,110 $ 782,590 $ 614,101 Europe 128,032 102,440 376,885 290,257 Asia Pacific 57,837 46,178 167,319 133,039 Middle East, Africa, and Latin America 13,077 10,791 38,484 30,911 Total revenues $ 476,111 $ 377,519 $ 1,365,278 $ 1,068,308
Long-Lived Assets by Geographic Area	Long-lived assets by geographic area are as follows as of the periods shown below (in thousands): October 31, January 31, Long-lived assets by geography North America $ 45,702 $ 46,285 Europe 5,285 5,525 Asia Pacific 1,368 1,359 Middle East, Africa, and Latin America $ 1,108 481 Total long-lived assets $ 53,463 $ 53,650

Short-Term Investments - Schedu

Short-Term Investments - Schedule of Short-Term Investments (Detail) - USD ($) $ in Thousands	Oct. 31, 2021	Jan. 31, 2021
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	$ 1,202,979	$ 929,273
Gross unrealized gains	1,133	3,879
Gross unrealized losses	(2,571)	(30)
Estimated fair value	1,201,541	933,122
Certificates of deposits
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	16,750	17,350
Gross unrealized gains	10	15
Gross unrealized losses	0	(1)
Estimated fair value	16,760	17,364
Asset-backed securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	190,558	125,833
Gross unrealized gains	152	745
Gross unrealized losses	(458)	(2)
Estimated fair value	190,252	126,576
Commercial paper
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	47,375	57,390
Gross unrealized gains	8	8
Gross unrealized losses	0	(2)
Estimated fair value	47,383	57,396
Corporate notes and bonds
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	642,377	428,710
Gross unrealized gains	809	2,360
Gross unrealized losses	(1,609)	(23)
Estimated fair value	641,577	431,047
Foreign government bonds
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	26,625	31,855
Gross unrealized gains	23	45
Gross unrealized losses	(57)	(2)
Estimated fair value	26,591	31,898
U.S. agency obligations
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	27,974	52,756
Gross unrealized gains	14	119
Gross unrealized losses	(50)	0
Estimated fair value	27,938	52,875
U.S. treasury securities
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	251,320	215,379
Gross unrealized gains	117	587
Gross unrealized losses	(397)	0
Estimated fair value	$ 251,040	$ 215,966

Short-Term Investments - Summar

Short-Term Investments - Summary of Estimated Fair Value of Short-Term Investments, Designated as Available-for-Sale and Classified by Contractual Maturity (Detail) - USD ($) $ in Thousands	Oct. 31, 2021	Jan. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Due in one year or less	$ 378,075	$ 428,155
Due in one to five years	823,466	504,967
Total	$ 1,201,541	$ 933,122

Short-Term Investments - Sche_2

Short-Term Investments - Schedule of Fair Values and Gross Unrealized Loss Position of Available-for-Sale Securities Aggregated by Investment Category (Detail) - USD ($) $ in Thousands	Oct. 31, 2021	Jan. 31, 2021
Certificates of deposits
Schedule of Available-for-sale Securities [Line Items]
Fair value		$ 3,749
Gross unrealized losses		(2)
Asset-backed securities
Schedule of Available-for-sale Securities [Line Items]
Fair value	$ 132,390	3,318
Gross unrealized losses	(458)	(1)
Commercial paper
Schedule of Available-for-sale Securities [Line Items]
Fair value	5,809	17,626
Gross unrealized losses	0	(2)
Corporate notes and bonds
Schedule of Available-for-sale Securities [Line Items]
Fair value	448,241	29,558
Gross unrealized losses	(1,609)	(23)
Foreign government bonds
Schedule of Available-for-sale Securities [Line Items]
Fair value	16,687	2,679
Gross unrealized losses	(57)	$ (2)
U.S. agency obligations
Schedule of Available-for-sale Securities [Line Items]
Fair value	24,924
Gross unrealized losses	(50)
U.S. treasury securities
Schedule of Available-for-sale Securities [Line Items]
Fair value	207,733
Gross unrealized losses	$ (397)

Deferred Costs - Additional Inf

Deferred Costs - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2021	Oct. 31, 2020	Jan. 31, 2021
Deferred Costs [Abstract]
Deferred costs	$ 34,091,000		$ 34,091,000		$ 42,072,000
Amortization of deferred costs	7,000,000	$ 5,000,000	19,000,000	$ 15,000,000
Impairment losses recorded in relation to the costs capitalized	$ 0	$ 0	$ 0	$ 0

Property and Equipment, Net - C

Property and Equipment, Net - Components of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Oct. 31, 2021	Jan. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 82,791	$ 83,266
Less accumulated depreciation	(29,328)	(29,616)
Total property and equipment, net	53,463	53,650
Land
Property, Plant and Equipment [Line Items]
Property and equipment, gross	3,040	3,040
Building
Property, Plant and Equipment [Line Items]
Property and equipment, gross	20,984	20,984
Land improvements and building improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	22,392	22,392
Equipment and computers
Property, Plant and Equipment [Line Items]
Property and equipment, gross	4,157	8,847
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	14,211	13,452
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	16,499	13,945
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,508	$ 606

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2021	Oct. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation	$ 2	$ 2	$ 5	$ 7

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2021	Oct. 31, 2020	Jan. 31, 2021
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Goodwill	$ 437,261		$ 437,261		$ 436,029
Amortization expense	$ 5,000	$ 5,000	$ 14,000	$ 15,000

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Details of Intangible Assets (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Oct. 31, 2021	Jan. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 172,842	$ 171,176
Accumulated amortization	(70,283)	(56,581)
Total	102,559	114,595
Existing technology
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	26,180	26,180
Accumulated amortization	(11,171)	(8,367)
Total	$ 15,009	$ 17,813
Remaining useful life (in years)	4 years	4 years 9 months 18 days
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 111,357	$ 110,643
Accumulated amortization	(35,976)	(27,741)
Total	$ 75,381	$ 82,902
Remaining useful life (in years)	7 years 3 months 18 days	8 years
Trade name/trademarks
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 13,900	$ 13,900
Accumulated amortization	(5,980)	(4,005)
Total	$ 7,920	$ 9,895
Remaining useful life (in years)	3 years	3 years 9 months 18 days
Other intangibles
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 21,405	$ 20,453
Accumulated amortization	(17,156)	(16,468)
Total	$ 4,249	$ 3,985
Remaining useful life (in years)	5 years 1 month 6 days	5 years 1 month 6 days

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Estimated Amortization Expense (Detail) - USD ($) $ in Thousands	Oct. 31, 2021	Jan. 31, 2021
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Remaining for 2022	$ 4,694
2023	18,623
2024	18,619
2025	17,717
2026	13,309
Thereafter	29,597
Total	$ 102,559	$ 114,595

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Oct. 31, 2021	Jan. 31, 2021
Payables and Accruals [Abstract]
Accrued commissions	$ 7,253	$ 7,498
Accrued bonus	4,523	4,134
Accrued vacation	5,688	4,716
Payroll tax payable	8,821	10,250
Accrued other compensation and benefits	5,831	3,812
Total accrued compensation and benefits	32,116	30,410
Accrued fees payable to salesforce.com	6,605	6,381
Taxes payable	12,397	13,598
Accrued third-party professional services subcontractors' fees	1,562	1,515
Other accrued expenses	15,567	9,488
Total accrued expenses and other current liabilities	$ 36,131	$ 30,982

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Oct. 31, 2021	Jan. 31, 2021
Assets
Short-term investments	$ 1,201,541	$ 933,122
Fair value, measurements recurring
Assets
Total financial assets	1,705,319	1,209,019
Liabilities
Total financial liabilities	34	72
Fair value, measurements recurring | Money market funds
Assets
Cash equivalents:	477,352	259,937
Fair value, measurements recurring | U.S. treasury securities
Assets
Cash equivalents:	20,499	15,520
Fair value, measurements recurring | Corporate notes and bonds
Assets
Cash equivalents:	5,855
Fair value, measurements recurring | Certificates of deposits
Assets
Short-term investments	16,760	17,364
Fair value, measurements recurring | Asset-backed securities
Assets
Short-term investments	190,252	126,576
Fair value, measurements recurring | Commercial paper
Assets
Short-term investments	47,383	57,396
Fair value, measurements recurring | Corporate notes and bonds
Assets
Short-term investments	641,577	431,047
Fair value, measurements recurring | Foreign government bonds
Assets
Short-term investments	26,591	31,898
Fair value, measurements recurring | U.S. agency obligations
Assets
Short-term investments	27,938	52,875
Fair value, measurements recurring | U.S. treasury securities
Assets
Short-term investments	251,040	215,966
Fair value, measurements recurring | Foreign currency derivative contracts
Assets
Short-term investments	72	440
Fair value, measurements recurring | Foreign currency derivative contracts
Liabilities
Foreign currency derivative contracts	34	72
Fair value, measurements recurring | Level 1
Assets
Total financial assets	477,352	259,937
Liabilities
Total financial liabilities	0	0
Fair value, measurements recurring | Level 1 | Money market funds
Assets
Cash equivalents:	477,352	259,937
Fair value, measurements recurring | Level 1 | U.S. treasury securities
Assets
Cash equivalents:	0	0
Fair value, measurements recurring | Level 1 | Corporate notes and bonds
Assets
Cash equivalents:	0
Fair value, measurements recurring | Level 1 | Certificates of deposits
Assets
Short-term investments	0	0
Fair value, measurements recurring | Level 1 | Asset-backed securities
Assets
Short-term investments	0	0
Fair value, measurements recurring | Level 1 | Commercial paper
Assets
Short-term investments	0	0
Fair value, measurements recurring | Level 1 | Corporate notes and bonds
Assets
Short-term investments	0	0
Fair value, measurements recurring | Level 1 | Foreign government bonds
Assets
Short-term investments	0	0
Fair value, measurements recurring | Level 1 | U.S. agency obligations
Assets
Short-term investments	0	0
Fair value, measurements recurring | Level 1 | U.S. treasury securities
Assets
Short-term investments	0	0
Fair value, measurements recurring | Level 1 | Foreign currency derivative contracts
Assets
Short-term investments	0	0
Fair value, measurements recurring | Level 1 | Foreign currency derivative contracts
Liabilities
Foreign currency derivative contracts	0	0
Fair value, measurements recurring | Level 2
Assets
Total financial assets	1,227,967	949,082
Liabilities
Total financial liabilities	34	72
Fair value, measurements recurring | Level 2 | Money market funds
Assets
Cash equivalents:	0	0
Fair value, measurements recurring | Level 2 | U.S. treasury securities
Assets
Cash equivalents:	20,499	15,520
Fair value, measurements recurring | Level 2 | Corporate notes and bonds
Assets
Cash equivalents:	5,855
Fair value, measurements recurring | Level 2 | Certificates of deposits
Assets
Short-term investments	16,760	17,364
Fair value, measurements recurring | Level 2 | Asset-backed securities
Assets
Short-term investments	190,252	126,576
Fair value, measurements recurring | Level 2 | Commercial paper
Assets
Short-term investments	47,383	57,396
Fair value, measurements recurring | Level 2 | Corporate notes and bonds
Assets
Short-term investments	641,577	431,047
Fair value, measurements recurring | Level 2 | Foreign government bonds
Assets
Short-term investments	26,591	31,898
Fair value, measurements recurring | Level 2 | U.S. agency obligations
Assets
Short-term investments	27,938	52,875
Fair value, measurements recurring | Level 2 | U.S. treasury securities
Assets
Short-term investments	251,040	215,966
Fair value, measurements recurring | Level 2 | Foreign currency derivative contracts
Assets
Short-term investments	72	440
Fair value, measurements recurring | Level 2 | Foreign currency derivative contracts
Liabilities
Foreign currency derivative contracts	$ 34	$ 72

Fair Value Measurements - Summa

Fair Value Measurements - Summary Fair Value of Outstanding Derivative Instruments (Detail) - Foreign currency derivative contracts - USD ($) $ in Thousands	Oct. 31, 2021	Jan. 31, 2021
Derivatives, Fair Value [Line Items]
Notional amount of foreign currency derivative contracts	$ 10,142	$ 52,516
Fair value of foreign currency derivative contracts	$ 10,104	$ 52,148

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Outstanding Balance Sheet Hedges (Detail) - Foreign currency derivative contracts - USD ($) $ in Thousands	Oct. 31, 2021	Jan. 31, 2021
Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Derivative Assets	$ 72	$ 440
Accrued expenses
Derivatives, Fair Value [Line Items]
Derivative Liabilities	$ 34	$ 72

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2021	Oct. 31, 2020
Income Tax Disclosure [Abstract]
Effective tax rates	20.70%	7.40%	15.90%	4.00%
Excess tax benefits recognized	$ 10,404	$ 17,329	$ 45,464	$ 59,067

Deferred Revenue, Performance_2

Deferred Revenue, Performance Obligations, and Unbilled Accounts Receivable - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2021	Oct. 31, 2020	Jan. 31, 2021
Revenue From Contracts With Customers [Line Items]
Unbilled accounts receivable	$ 67,970		$ 67,970		$ 47,206
Subscription services
Revenue From Contracts With Customers [Line Items]
Recognition of deferred revenue	296,000	$ 232,000	535,000	$ 409,000
Revenue expected to be recognized from remaining performance obligations	1,037,000		1,037,000
Unbilled accounts receivable	38,000		38,000		27,000
Professional services and other
Revenue From Contracts With Customers [Line Items]
Unbilled accounts receivable	$ 30,000		$ 30,000		$ 20,000

Deferred Revenue, Performance_3

Deferred Revenue, Performance Obligations, and Unbilled Accounts Receivable - Performance Obligation Duration (Details) - Subscription services - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-11-01	Oct. 31, 2021
Revenue From Contracts With Customers [Line Items]
Revenue, remaining performance obligation, percentage	73.00%
Revenue, remaining performance obligation, recognition period	12 months

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2021	Oct. 31, 2020
Leases [Line Items]
Operating lease expense	$ 3	$ 3	$ 10	$ 9
Maximum
Leases [Line Items]
Operating leases, options to extend leases term	9 years		9 years
Finance leases, options to extend leases term	9 years		9 years

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information Related to Leases (Detail) - USD ($) $ in Thousands	9 Months Ended
	Oct. 31, 2021	Oct. 31, 2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 10,288	$ 8,149
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$ 2,135	$ 8,937

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information Related to Leases (Detail) - USD ($) $ in Thousands	Oct. 31, 2021	Jan. 31, 2021
Operating Leases
Lease right-of-use assets	$ 50,499	$ 56,917
Lease liabilities	$ 10,803	$ 11,347
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]
Lease liabilities, noncurrent	$ 45,237	$ 51,393
Total operating lease liabilities	$ 56,040	$ 62,740
Weighted Average Remaining Lease Term	6 years 3 months 18 days	6 years 8 months 12 days
Weighted Average Discount Rate	3.80%	3.80%

Leases- Maturities of lease lia

Leases- Maturities of lease liabilities (Detail) - USD ($) $ in Thousands	Oct. 31, 2021	Jan. 31, 2021
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
Remaining for 2022	$ 3,354
2023	11,555
2024	11,404
2025	8,490
2026	7,326
Thereafter	21,128
Total lease payments	63,257
Less imputed interest	7,217
Total	$ 56,040	$ 62,740

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stock Option Activity (Detail) $ / shares in Units, $ in Millions	9 Months Ended	12 Months Ended
	Oct. 31, 2021USD ($)$ / sharesshares	Jan. 31, 2021USD ($)$ / sharesshares
Number of shares
Options outstanding, Beginning balance (in shares) | shares	12,761,289
Options granted (in shares) | shares	1,081,518
Options exercised (in shares) | shares	(1,074,939)
Options forfeited/cancelled (in shares) | shares	(267,795)
Options outstanding, Ending balance (in shares) | shares	12,500,073	12,761,289
Options vested and exercisable (in shares) | shares	7,197,020
Options vested and exercisable and expected to vest thereafter (in shares) | shares	12,500,073
Weighted average exercise price
Options outstanding, Beginning balance (in usd per share) | $ / shares	$ 57.48
Options granted (in usd per share) | $ / shares	278.07
Options exercised (in usd per share) | $ / shares	40.29
Options forfeited/cancelled (in usd per share) | $ / shares	166.28
Options outstanding, Ending balance (in usd per share) | $ / shares	75.71	$ 57.48
Options vested and exercisable (in usd per share) | $ / shares	28.82
Options vested and exercisable and expected to vest thereafter (in usd per share) | $ / shares	$ 75.71
Weighted average remaining contractual term (in years), Options outstanding	4 years 9 months 18 days	5 years
Weighted average remaining contractual term (in years), Options vested and exercisable	2 years 9 months 18 days
Weighted average remaining contractual term (in years), Options vested and exercisable and expected to vest thereafter	4 years 9 months 18 days
Aggregate intrinsic value (in millions)
Options outstanding | $	$ 3,016	$ 2,794
Options vested and exercisable | $	2,074
Options vested and exercisable and expected to vest thereafter | $	$ 3,016

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) $ / shares in Units, $ in Millions	3 Months Ended	9 Months Ended
	Oct. 31, 2021USD ($)$ / shares	Oct. 31, 2021USD ($)$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to unvested stock options granted	$ 250	$ 250
Intrinsic value of options exercised	$ 52	$ 267
2013 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value of options granted (in usd per share) | $ / shares	$ 117.20	$ 108.90
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period of unvested stock (in years)		2 years 9 months 18 days
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period of unvested stock (in years)		1 year 1 month 6 days
Unrecognized compensation cost related to unvested RSUs	$ 113	$ 113
Total intrinsic value, vested	$ 61	$ 195

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Weighted-Average Assumptions Used to Estimate Grant Date Fair Value of Options Granted (Detail) - Stock Options	3 Months Ended		9 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2021	Oct. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	37.00%
Expected term (in years)	6 years 3 months	6 years 3 months	6 years 3 months
Risk-free interest rate, Minimum	0.90%	0.33%	0.68%	0.33%
Risk-free interest rate, Maximum	1.30%	0.45%	1.30%	1.43%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility		39.00%	37.00%	39.00%
Expected term (in years)				6 years 3 months
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility		40.00%	39.00%	41.00%
Expected term (in years)				7 years 3 months

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Restricted Stock Unit (RSU) Activity (Detail) - Restricted Stock Units (RSUs)	9 Months Ended
	Oct. 31, 2021$ / sharesshares
Unreleased restricted stock units
Beginning Balance (in shares) | shares	1,032,215
RSUs granted (in shares) | shares	442,514
RSUs vested (in shares) | shares	(663,283)
RSUs forfeited/cancelled (in shares) | shares	(57,443)
Ending Balance (in shares) | shares	754,003
Weighted  average grant date fair value
Beginning Balance (in usd per share) | $ / shares	$ 121.98
RSUs granted (in usd per share) | $ / shares	280.61
RSUs vested (in usd per share) | $ / shares	164.02
RSUs forfeited/cancelled (in usd per share) | $ / shares	177.20
Ending Balance (in usd per share) | $ / shares	$ 173.86

Net Income per Share - Numerato

Net Income per Share - Numerators and Denominators of the Basic and Diluted EPS Computations for Common Stock (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2021	Oct. 31, 2020
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Weighted average shares used in computing net income per share, basic (in shares)	153,514	150,993	153,020	150,322
Net income per share, basic (in usd per share)	$ 0.69	$ 0.64	$ 2.16	$ 1.84
Reallocation as a result of conversion of Class B to Class A common stock:
Weighted average shares used in computing net income per share, diluted (in shares)	163,034	161,711	162,663	160,517
Net income per share, diluted (in usd per share)	$ 0.65	$ 0.60	$ 2.03	$ 1.73
Class A common stock
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Net income, basic	$ 95,691	$ 87,262	$ 298,379	$ 249,155
Weighted average shares used in computing net income per share, basic (in shares)	138,755	135,892	138,234	135,172
Net income per share, basic (in usd per share)	$ 0.69	$ 0.64	$ 2.16	$ 1.84
Reallocation as a result of conversion of Class B to Class A common stock:
Net income, basic	$ 10,178	$ 9,697	$ 31,915	$ 27,925
Reallocation of net income to Class B common stock	0	0	0	0
Net income, diluted	$ 105,869	$ 96,959	$ 330,294	$ 277,080
Conversion of Class B to Class A common stock (in shares)	14,759	15,101	14,786	15,150
Effect of potentially dilutive common shares (in shares)	9,520	10,718	9,643	10,195
Weighted average shares used in computing net income per share, diluted (in shares)	163,034	161,711	162,663	160,517
Net income per share, diluted (in usd per share)	$ 0.65	$ 0.60	$ 2.03	$ 1.73
Class B common stock
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Net income, basic	$ 10,178	$ 9,697	$ 31,915	$ 27,925
Weighted average shares used in computing net income per share, basic (in shares)	14,759	15,101	14,786	15,150
Net income per share, basic (in usd per share)	$ 0.69	$ 0.64	$ 2.16	$ 1.84
Reallocation as a result of conversion of Class B to Class A common stock:
Net income, basic	$ 0	$ 0	$ 0	$ 0
Reallocation of net income to Class B common stock	5,588	5,784	17,690	15,825
Net income, diluted	$ 15,766	$ 15,481	$ 49,605	$ 43,750
Conversion of Class B to Class A common stock (in shares)	0	0	0	0
Effect of potentially dilutive common shares (in shares)	9,520	10,718	9,643	10,195
Weighted average shares used in computing net income per share, diluted (in shares)	24,279	25,819	24,429	25,345
Net income per share, diluted (in usd per share)	$ 0.65	$ 0.60	$ 2.03	$ 1.73

Net Income per Share - Potentia

Net Income per Share - Potential Common Share Equivalents Excluded where the Inclusion would be Anti-dilutive (Detail) - shares	3 Months Ended		9 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2021	Oct. 31, 2020
Earnings Per Share [Abstract]
Options and awards to purchase shares not included in the computation of diluted net income per share because their inclusion would be anti-dilutive (in shares)	1,105,478	85,099	869,044	997,236

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Mar. 13, 2017USD ($)	Jan. 26, 2017employee	Oct. 31, 2021USD ($)
Value-Added Reseller Agreement
Long-term Purchase Commitment [Line Items]
Minimum order commitment			$ 500,000,000
IQVIA Litigation Matter | Minimum
Long-term Purchase Commitment [Line Items]
Monetary damages	$ 200,000,000
Medidata Litigation Matter
Long-term Purchase Commitment [Line Items]
Number of former employees | employee		5
Present to September 1st, 2025 | Value-Added Reseller Agreement
Long-term Purchase Commitment [Line Items]
Minimum order commitment			500,000,000
March 1st 2014 to September 1st, 2020 | Value-Added Reseller Agreement
Long-term Purchase Commitment [Line Items]
Amount of first minimum order commitment met			$ 250,000,000

Revenues by Product - Summary o

Revenues by Product - Summary of Total Revenues (Detail) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2021USD ($)productArea	Oct. 31, 2020USD ($)	Oct. 31, 2021USD ($)productArea	Oct. 31, 2020USD ($)
Disaggregation of Revenue [Line Items]
Number of product areas | productArea	2		2
Total revenues	$ 476,111	$ 377,519	$ 1,365,278	$ 1,068,308
Total subscription services
Disaggregation of Revenue [Line Items]
Total revenues	380,738	302,938	1,088,293	856,675
Commercial Solutions
Disaggregation of Revenue [Line Items]
Total revenues	223,183	189,874	649,156	547,341
R&D Solutions
Disaggregation of Revenue [Line Items]
Total revenues	157,555	113,064	439,137	309,334
Total professional services
Disaggregation of Revenue [Line Items]
Total revenues	95,373	74,581	276,985	211,633
Commercial Solutions
Disaggregation of Revenue [Line Items]
Total revenues	41,675	36,613	124,241	104,859
R&D Solutions
Disaggregation of Revenue [Line Items]
Total revenues	$ 53,698	$ 37,968	$ 152,744	$ 106,774

Information about Geographic _3

Information about Geographic Areas - Revenues by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Oct. 31, 2021	Oct. 31, 2020
Revenues by geography
Total revenues	$ 476,111	$ 377,519	$ 1,365,278	$ 1,068,308
North America
Revenues by geography
Total revenues	277,165	218,110	782,590	614,101
Europe
Revenues by geography
Total revenues	128,032	102,440	376,885	290,257
Asia Pacific
Revenues by geography
Total revenues	57,837	46,178	167,319	133,039
Middle East, Africa, and Latin America
Revenues by geography
Total revenues	$ 13,077	$ 10,791	$ 38,484	$ 30,911

Information about Geographic _4

Information about Geographic Areas - Long-Lived Assets by Geographic Area (Detail) - USD ($) $ in Thousands	Oct. 31, 2021	Jan. 31, 2021
Long-lived assets by geography
Total long-lived assets	$ 53,463	$ 53,650
North America
Long-lived assets by geography
Total long-lived assets	45,702	46,285
Europe
Long-lived assets by geography
Total long-lived assets	5,285	5,525
Asia Pacific
Long-lived assets by geography
Total long-lived assets	1,368	1,359
Middle East, Africa, and Latin America
Long-lived assets by geography
Total long-lived assets	$ 1,108	$ 481